What immune cell features are most predictive of COVID outcomes? @mkuchroo@JcsHuang Patrick Wong et al used ML algorithm Multiscale PHATE to assign each immune cell type in COVID patients a mortality-likelihood score. Latest from @KrishnaswamyLab 💪🏼 (1/) go.nature.com/3K0QCqi
Based on the flow cytometry data on 54 million cells from COVID 168 patients, the low density granulocytes (neutrophils and eosinophils) were the most enriched cell types in patients who had fatal COVID, followed by inflammatory monocytes and certain B cell subsets. (2/)
In contrast, T cells (most of them; see below), NK cells and dendritic cells were associated with the lowest mortality likelihood scores. They are likely protecting the host from lethal disease. (3/)
When you dive into each of the lymphocyte subsets though, things start to look very interesting. Among the CD4 T subsets, while Th1, IL-4+, IL-6+ cells are protective, IL-17* cells that also produce IFN-g & granzyme B (red) have the highest mortality likelihood score. (4/)
Within the CD8 T cell subsets, hyperactivated CD8+ T cell (CD8+CD45RA+TIM3+HLA-DR+PD1+) TEMRA cells expressing granzyme B were correlated with lethality, while naive cells had the lowest mortality likelihood score. (5/)
The beneficial vs. pathogenic roles of T cells in COVID have been noted before. However, the Multiscale PHATE assigned vastly different mortality scores to each T cell subset with distinct effector functions. Seeing this from @mkuchroo was definitely a wow moment for me. (6/)
What about B cells? Plasmablasts (brown) had highest mortality likelihood score. In contrast, a subset of late-activated mature B cells defined by CD86+ (green) was most enriched in patients with good outcomes. Consistent with a previous study. pubmed.ncbi.nlm.nih.gov/32910469/ (7/)
We are so fortunate to work with Dr. @KrishnaswamyLab and her team on this project. Her team keeps innovating new techniques to analyze complex and massive data with method that can learn and visualize cellular features - something immunologists love to do ❤️ (8/)
But they are just getting started 💪🏼 @KrishnaswamyLab also found a way to generate hard to obtain data from easy to obtain ones. For example, they can use ‘feature mapping GAN’ to model patients' flow cytometry data from clinical monitoring data 🤯 (9/)
This collaboration highlights the power of interdisciplinary research. When immunologists work together with computer scientists, amazing insights can emerge (there’s a lot more in this paper). Highlighting all the authors who contributed to the study 👇🏽 (end)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Published today! Victoria Bastos, @KerrieGreene_ et al found two distinct immunotypes of ME/CFS based on the cerebrospinal fluid analysis. Great collaboration with @MBVanElzakker @microbeminded2 and the Bragée clinic in Sweden. (1/) academic.oup.com/jimmunol/artic…
This is perfect timing as Victoria will present these data at the @polybioRF symposium today. (2/)
Based on cerebrospinal fluid cytokines, we identified two clusters of ME/CFS patients. Cluster 1 had elevated matrix metalloproteinases & many cytokines compared to cluster 2. Other than older age (Cluster 1), clinical presentation of these clusters was similar. (3/)
Published today📣
Our nasal booster in the "Prime & Spike" vaccine works without adjuvants (which are needed to induce adaptive immunity but also cause inflammation). @Kwon_Dongil @tianyangmao @BenIsraelow et al. asked how this is possible. (1/) nature.com/articles/s4159…
Prime & Spike is a vaccine strategy that leverages preexisting immunity primed by conventional vaccines to elicit mucosal IgA and T cell responses that prevent COVID infection and transmission in rodents. The nasal booster is simply the spike protein (2/) science.org/doi/10.1126/sc…
Our new study shows that the nasal spike protein booster converts lymph node memory B cells into IgA-secreting cells in the lung with the help of memory CD4 T cells. Ag-specific CD4 T cells replace all the necessary functions of adjuvants without nonspecific inflammation! (3/)
This prospective observational study led by @connorbgrady @bornali_27 @SilvaJ_C @hmkyale examined the impact of the primary COVID-19 vaccination on the symptoms and immune signatures of 16 people with #longCOVID. Here is what we found 👇🏼 (1/)
This study asked: Does COVID vaccination improve symptoms of long COVID? If so, is the improvement due to robust T and B cell responses leading to the clearance of the viral reservoir? If not, is there an immune feature that predicts worsening of LC? (2/)
The self-reported impact of vaccination was variable. Of the 16 long COVID patients, 10 felt better, 3 had no change, and 3 had worse health (1 hospitalized) 12 weeks after vaccination. Both physical and social effects of symptom burden appeared to decrease after vaccination. (3/)
Our preprint on post-vaccination syndrome is out. We studied immune signatures and examined spike protein in the blood of people who have developed chronic illnesses after COVID-19 vaccination. (1/) medrxiv.org/content/10.110…
Vaccines have saved countless lives and inspired me to become an immunologist. While generally safe, some people experience adverse effects, including Post-Vaccination Syndrome (PVS). Studying PVS is crucial for improving patient care and enhancing vaccine safety & acceptance. (2/) pubmed.ncbi.nlm.nih.gov/37986769/
Happy to share our latest work by @YYexin et al. on antibody-mediated control of endogenous retroviruses in mice. In the process, we found “natural antibodies” with broad reactivity against enveloped viruses. Here is how “panviral” antibodies work 🧵(1/)
Endogenous retroviruses (ERV) are remnants of genetic invaders that have integrated into our ancestors' genomes over millions of years. ERVs occupy ~8% of the human genome and are under constant host immune surveillance. (2/) nature.com/articles/nrg31… nature.com/articles/nrmic…
This work started over 7 years ago when @YYexin and @rebecca_treger began to examine why ERVs reactivate in certain mouse strains. Through many genetic crosses, we figured out that secreted IgM recruits complement to suppress infectious ERV from emerging. (3/)
This time, we developed a nasal booster vaccine for influenza viruses. In this preprint, @MiyuMoriyama et al. show that nasal boosters with unadjuvanted hemagglutinin protein induce sterilizing immunity in mice against flu. (1/) biorxiv.org/content/10.110…
This work builds on the Prime and Spike vaccine strategy by @tianyangmao @BenIsraelow et al. against COVID where mRNA vaccine followed by nasal booster with recombinant spike protein established local immunity, ⬇️ infection & transmission in rodents. (2/) science.org/doi/10.1126/sc…
For Prime and HA against flu, @MiyuMoriyama tested several different mRNA IM prime and nasal HA booster doses, followed by a homologous influenza virus challenge. Like Prime and Spike, no adjuvant is needed for the nasal booster due to preexisting immunity from Prime. (3/)